Table 6 VDR polymorphims sub grouping in PCa cases according to clinical parameters
From: Association of vitamin D receptor variants with clinical parameters in prostate cancer
Polymorphisms | PSA N (%) | Gleason N (%) | TNM N (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genotypes | <10 ng/mL | ≥10 ng/mL | Odds (95 % CI) | P | <7 | ≥7 | Odds (95 % CI) | P | T1-T2 | T3 | Odds (95 % CI) | P |
FokI | ||||||||||||
CC | 21 (21.88) | 16 (16.67) | 1.00 | 26 (24.53) | 18 (16.98) | 1.00 | 16 (22.22) | 16 (22.22) | 1.00 | |||
CT | 25 (26.04) | 24 (25.00) | 0.79 (0.34–1.87) | 0.76 | 27 (25.47) | 21 (19.81) | 0.89 (0.39–2.04) | 0.95 | 24 (33.33) | 8 (11.11) | 3.00 (1.04–8.65) | 0.07 |
TT | 7 (7.29) | 3 (3.13) | 1.78 (0.40–7.97) | 0.69 | 7 (6.60) | 7 (6.60) | 0.69 (0.21–2.32) | 0.77 | 5 (6.94) | 3 (4.17) | 1.67 (0.34–8.18) | 0.81 |
BsmI | ||||||||||||
AA | 2 (2.08) | 9 (9.38) | 1.00 | 8 (7.55) | 4 (3.77) | 1.00 | 8 (11.11) | 2 (2.78) | 1.00 | |||
AG | 23 (23.96) | 20 (20.83) | 5.18 (1.00–26.82) | 0.08 | 25 (23.58) | 21 (19.81) | 0.60 (0.16–2.26) | 0.66 | 16 (22.22) | 11 (15.28) | 0.36 (0.07–2.05) | 0.43 |
GG | 28 (29.17) | 14 (14.58) | 9.00 (1.71–47.39) | 0.01* | 27 (25.47) | 21 (19.81) | 0.64 (0.17–2.43) | 0.74 | 21 (29.17) | 14 (19.44) | 0.38 (0.07–2.03) | 0.43 |
Genotypes in pairs | ||||||||||||
BsmI - ApaI | ||||||||||||
AATT | 2 (2.11) | 9 (9.47) | 1.00 | 8 (8.25) | 4 (4.12) | 1.00 | 8 (12.70) | 2 (3.17) | 1.00 | |||
AGTT | 10 (10.53) | 7 (7.37) | 6.43 (1.05–39.33) | 0.08 | 9 (9.28) | 6 (6.19) | 0.75 (0.15–3.65) | 0.97 | 7 (11.11) | 4 (6.35) | 0.44 (ND) | 0.73 |
GGGT | 9 (9.47) | 5 (5.26) | 8.10 (1.23–53.20) | 0.06 | 4 (4.12) | 6 (6.19) | 0.33 (0.06–1.91) | 0.41 | 4 (6.35) | 4 (6.35) | 0.25 (ND) | 0.40 |
AGGT | 12 (12.63) | 13 (13.68) | 4.15 (0.74–23.23) | 0.19 | 15 (15.46) | 15 (15.46) | 0.50 (0.12–2.02) | 0.52 | 9 (14.29) | 6 (9.52) | 0.38 (0.06–2.41) | 0.54 |
GGGG | 13 (13.68) | 6 (6.32) | 9.75 (1.59–59.70) | 0.02* | 12 (12.37) | 7 (7.22) | 0.86 (0.19–3.92) | 0.85 | 7 (11.11) | 4 (6.35) | 0.44 (ND) | 0.73 |
GGTT | 6 (6.32) | 3 (3.16) | 9.00 (ND) | 0.08 | 4 (4.12) | 6 (6.19) | 0.33 (0.06–1.91) | 0.41 | 4 (6.35) | 4 (6.35) | 0.25 (ND) | 0.40 |
Dominant model | ||||||||||||
BsmI | ||||||||||||
AA + AG | 25 (26.04) | 29 (30.21) | 1.00 | 33 (31.43) | 25 (23.81) | 1.00 | 24 (33.33) | 13 (18.06) | 1.00 | |||
GG | 28 (29.17) | 14 (14.58) | 2.32 (1.01–5.35) | 0.07 | 26 (24.76) | 21 (20.00) | 0.94 (0.43–2.04) | 0.97 | 21 (29.17) | 14 (19.44) | 0.81 (0.31–2.11) | 0.86 |
Recessive model | ||||||||||||
FokI | ||||||||||||
CC | 21 (21.88) | 16 (16.67) | 1.00 | 25 (23.81) | 18 (17.14) | 1.00 | 16 (22.22) | 16 (22.22) | 1.00 | |||
CT + TT | 32 (33.33) | 27 (28.13) | 0.90 (0.40–2.07) | 0.98 | 34 (32.38) | 28 (26.67) | 0.87 (0.40–1.92) | 0.89 | 29 (40.28) | 11 (15.28) | 2.64 (0.99–7.03) | 0.09 |
TaqI | ||||||||||||
TT | 29 (30.21) | 15 (15.63) | 1.00 | 27 (25.71) | 22 (20.95) | 1.00 | 21 (29.17) | 17 (23.61) | 1.00 | |||
TC + CC | 24 (25.00) | 28 (29.17) | 0.44 (0.19–1.02) | 0.08 | 32 (30.48) | 24 (22.86) | 1.09 (0.50–2.35) | 0.99 | 24 (33.33) | 10 (13.89) | 1.94 (0.73–5.16) | 0.27 |
BsmI | ||||||||||||
AA | 2 (2.08) | 9 (9.38) | 1.00 | 8 (7.62) | 4 (3.81) | 1.00 | 8 (11.11) | 2 (2.78) | 1.00 | |||
AG + GG | 51 (53.13) | 34 (35.42) | 6.75 (1.37–33.18) | 0.02* | 51 (48.57) | 42 (40.00) | 0.61 (0.17–2.16) | 0.64 | 37 (51.39) | 25 (34.72) | 0.37 (0.07–1.89) | 0.38 |